Ladenburg Thalmann Downgrades Nile Therapeutics (NLTX) to Neutral
More News related to NLTX
- Nile Therapeutics to Present at BIO CEO and Investor Conference
- Nile Therapeutics (NLTX) Misses Q3 EPS by 3c
- Nile Therapeutics (NLTX) Announces Private Placement, Raising $3.4M
- Ladenburg Thalmann Downgrades Nile Therapeutics (NLTX) to Neutral
- Nile Therapeutics (NLTX) Misses Q2 EPS by 4c
More News related to Downgrades
- Argus Downgrades Sterlite Industries (SLT) to Sell
- Howard Weil Downgrades Bristow Group (BRS) to Market Perform
- RBC Downgrades Allied Nevada Gold (ANV) to Sector Perform
- RBC Capital Downgrades Suncor Energy (SU) to Sector Perform
- UBS Cuts Energy Conversion Devices (ENER) to Sell
Ladenburg Thalmann downgrades Nile Therapeutics (Nasdaq: NLTX) from Buy to Neutral.
Nile Therapeutics, Inc., a development stage biopharmaceutical company, develops and commercializes products for the treatment of cardiovascular disease in the United States.
Related Categories
DowngradesStocks Mentioned
-0.02Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
